Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial.
Teresa MichiChiara MattanaLuca S MengaMaria Grazia BocciMelania CesaranoTommaso RosàMaria Rosaria GualanoJonathan MontomoliSavino SpadaroMatteo TosatoElisabetta RotaFrancesco LandiSalvatore L CutuliEloisa S TanzarellaGabriele PintaudiEdoardo PiervincenziGiuseppe BelloTommaso TonettiPaola RucciGennaro De PascaleSalvatore M MaggioreDomenico Luca GriecoGiorgio ContiMassimo Antonellinull nullPublished in: Journal of intensive care (2023)
In patients with COVID-19 hypoxemic respiratory failure, treatment with helmet NIV or high-flow oxygen yielded similar quality of life and functional outcome at 6 months. The need for invasive mechanical ventilation was associated with worse outcomes. These data indicate that helmet NIV, as applied in the HENIVOT trial, can be safely used in hypoxemic patients. Trial registration Registered on clinicaltrials.gov NCT04502576 on August 6, 2020.
Keyphrases
- respiratory failure
- mechanical ventilation
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- intensive care unit
- end stage renal disease
- study protocol
- coronavirus disease
- sars cov
- clinical trial
- chronic kidney disease
- positive airway pressure
- ejection fraction
- phase ii
- phase iii
- newly diagnosed
- electronic health record
- randomized controlled trial
- adipose tissue
- patient reported outcomes
- peritoneal dialysis
- type diabetes
- metabolic syndrome
- obstructive sleep apnea
- machine learning
- artificial intelligence
- smoking cessation
- weight loss
- replacement therapy
- respiratory syndrome coronavirus
- sleep apnea